Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis
Allison A. Throm, Joshua B. Alinger, Jeanette T. Pingel, Allyssa L. Daugherty, Lauren M. Pachman, Anthony R. French
Allison A. Throm, Joshua B. Alinger, Jeanette T. Pingel, Allyssa L. Daugherty, Lauren M. Pachman, Anthony R. French
View: Text | PDF
Research Article Immunology

Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis

  • Text
  • PDF
Abstract

Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and muscle weakness. To delineate signaling abnormalities in JDM, mass cytometry was performed with PBMCs from treatment-naive JDM patients and controls. NK cell percentages were lower while frequencies of naive B cells and naive CD4+ T cells were higher in JDM patients than in controls. These cell frequency differences were attenuated with cessation of active disease. A large number of signaling differences were identified in treatment-naive JDM patients compared with controls. Classification models incorporating feature selection demonstrated that differences in phospholipase Cγ2 (PLCγ2) phosphorylation comprised 10 of 12 features (i.e., phosphoprotein in a specific immune cell subset) distinguishing the 2 groups. Because NK cells represented 5 of these 12 features, further studies focused on the PLCγ2 pathway in NK cells, which is responsible for stimulating calcium flux and cytotoxic granule movement. No differences were detected in upstream signaling or total PLCγ2 protein levels. Hypophosphorylation of PLCγ2 and downstream mitogen-activated protein kinase-activated protein kinase 2 were partially attenuated with cessation of active disease. PLCγ2 hypophosphorylation in treatment-naive JDM patients resulted in decreased calcium flux. The identification of dysregulation of PLCγ2 phosphorylation and decreased calcium flux in NK cells provides potential mechanistic insight into JDM pathogenesis.

Authors

Allison A. Throm, Joshua B. Alinger, Jeanette T. Pingel, Allyssa L. Daugherty, Lauren M. Pachman, Anthony R. French

×

Figure 3

Treatment-naive JDM patient NK cells hypophosphorylate PLCγ2 and MAPKAPK2 but not Syk/ZAP70 and Itk/Btk in comparison with controls over stimulation time course (tested with 2-way Welch’s t tests with Benjamini-Hochberg multiple hypothesis correction for 12 tests).

Options: View larger image (or click on image) Download as PowerPoint
Treatment-naive JDM patient NK cells hypophosphorylate PLCγ2 and MAPKAPK...
Open circles denote treatment-naive patients (n = 17). Filled squares denote healthy controls (n = 17). Data are displayed as the arcsinh ratio of the median intensity of the sample normalized to the run control. (A) NK cell PLCγ2 (0-min P = 6.88 × 10–8, 3-min P = 1.62 × 10–6, and 15-min P = 1.47 × 10–6) phosphorylation differs between treatment-naive JDM patients and controls. (B) NK cell Syk/ZAP70 and (C) Itk/Btk phosphorylation are not different between treatment-naive JDM patients and controls. (D) MAPKAPK2 (0-min P = 0.003, 3-min P = 0.002, and 15-min P = 0.0008) phosphorylation differs over the time course between 17 treatment-naive JDM patients and 17 controls. Error bars represent the mean ± SEM. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts